Cargando…

Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases

Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Savelli, Giordano, Muni, Alfredo, Barbieri, Roberto, Valmadre, Giuseppe, Biasiotto, Giorgio, Minari, Chiara, Ghimenton, Claudio, Pagani, Renato, Pecini, Elisa, Falcone, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649877/
https://www.ncbi.nlm.nih.gov/pubmed/29147381
http://dx.doi.org/10.14740/wjon739w
_version_ 1783272624094183424
author Savelli, Giordano
Muni, Alfredo
Barbieri, Roberto
Valmadre, Giuseppe
Biasiotto, Giorgio
Minari, Chiara
Ghimenton, Claudio
Pagani, Renato
Pecini, Elisa
Falcone, Matteo
author_facet Savelli, Giordano
Muni, Alfredo
Barbieri, Roberto
Valmadre, Giuseppe
Biasiotto, Giorgio
Minari, Chiara
Ghimenton, Claudio
Pagani, Renato
Pecini, Elisa
Falcone, Matteo
author_sort Savelli, Giordano
collection PubMed
description Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which (68)Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy.
format Online
Article
Text
id pubmed-5649877
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-56498772017-11-16 Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases Savelli, Giordano Muni, Alfredo Barbieri, Roberto Valmadre, Giuseppe Biasiotto, Giorgio Minari, Chiara Ghimenton, Claudio Pagani, Renato Pecini, Elisa Falcone, Matteo World J Oncol Case Report Prostate cancer is the second most commonly diagnosed neoplasm in men. This neoplasm has usually excellent prognosis, mostly consequent to the early diagnosis and the effective hormonal therapy. However, significant percentages of patients treated with total androgen blockade therapy, escape to treatment and evolve toward a more aggressive type of cancer. This clinical entity, named castration-resistant prostate cancer, has few and less effective therapeutic opportunities. Therefore, any additional information concerning possible biological targets to therapy is welcome. Here we describe two cases in which (68)Ga-DOTANOC PET/CT evidenced the somatostatin receptor overexpression by prostate metastases. The presence of these receptors may support with a more strong evidence the possibility to administer somatostatin analogs as an adjuvant therapy. Elmer Press 2014-04 2014-05-06 /pmc/articles/PMC5649877/ /pubmed/29147381 http://dx.doi.org/10.14740/wjon739w Text en Copyright 2014, Savelli et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Savelli, Giordano
Muni, Alfredo
Barbieri, Roberto
Valmadre, Giuseppe
Biasiotto, Giorgio
Minari, Chiara
Ghimenton, Claudio
Pagani, Renato
Pecini, Elisa
Falcone, Matteo
Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
title Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
title_full Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
title_fullStr Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
title_full_unstemmed Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
title_short Neuroendocrine Differentiation of Prostate Cancer Metastases Evidenced “in Vivo” by (68)Ga-DOTANOC PET/CT: Two Cases
title_sort neuroendocrine differentiation of prostate cancer metastases evidenced “in vivo” by (68)ga-dotanoc pet/ct: two cases
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649877/
https://www.ncbi.nlm.nih.gov/pubmed/29147381
http://dx.doi.org/10.14740/wjon739w
work_keys_str_mv AT savelligiordano neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT munialfredo neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT barbieriroberto neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT valmadregiuseppe neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT biasiottogiorgio neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT minarichiara neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT ghimentonclaudio neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT paganirenato neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT pecinielisa neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases
AT falconematteo neuroendocrinedifferentiationofprostatecancermetastasesevidencedinvivoby68gadotanocpetcttwocases